Adamis Pharmaceuticals Corporation ("we," "us," "our," "Adamis" or the
"company") is a specialty biopharmaceutical company focused on developing and
commercializing products in various therapeutic areas, including respiratory
disease, allergy and opioid overdose. Our products and product candidates in the
allergy, respiratory, and opioid overdose markets include: SYMJEPI(TM)
(epinephrine) Injection 0.3mg, which was approved by the U.S.